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Review
The National Blood Group Reference Laboratory (NBGRL) 
was established by Dr. Cyril Levene in 1971 to assist in the 
resolution of complex serology problems caused by common 
and rare antibodies to red blood cell (RBC) antigens throughout 
Israel.1 The first rare blood unit was frozen June 24, 1975. 
Over the years, the NBGRL resolved unusual cases by using 
rare RBCs and antibodies made available through the Serum, 
Cells, and Rare Fluids (SCARF) program. Rare units of blood 
were provided by Magen David Adom National Blood Services 
(MDA-NBS) according to the specificity determined by the 
NBGRL. The NBGRL was transferred from the Ministry 
of Health laboratories to MDA-NBS in 1995. Since 1995, 
the NBGRL coordinates the testing and identification of all 
unresolved blood types and RBC antibodies with the provision 
of compatible units of blood for patients in need. This includes 
common antigen-negative combinations and rare units of 
blood. Supply of rare units of blood is either from “on the shelf” 
liquid units or from our frozen rare blood inventory. Donor 
and rare unit data are registered and secured in the MDA-NBS 
database.2
A unit of blood that is negative for a high-prevalence 
antigen is considered rare if the antigen’s prevalence is less 
than 1 in 1000 in the Israeli population.3 Throughout the 
years, several rare blood types such as ABTI–, JMH variant, 
Dr(a–), K:–22, LU:–20, and RAPH:–1 were first recognized 
in Israel.1,2 These were mainly confirmed at the International 
Blood Group Reference Laboratory (IBGRL, Bristol, UK). 
Table 1 summarizes data on active rare blood donors and 
available frozen units through December 2014. During 2014, 
136 rare units of blood were requested and 111 were issued 
(82%). 
Most of the unfilled requests in 2014 were for one patient 
with anti-Yta (20 of 104) for whom the clinical necessity for 
this high-prevalence antigen negative blood was controversial. 
In 2012 and 2013, 12 percent and 16 percent of requests 
were not completed, respectively. A lower rate (7.9%) of 
unfilled requests for high-prevalence antigen negative units 
was reported by the American Rare Donor Program.4 Almost 
all the unfulfilled requests were due to the hospitals decision 
to postpone transfusion until a liquid unit was available or to 
transfuse fewer units than originally requested. 
Despite the lack of a hemovigilance system, which 
mandates reporting on the transfusion of incompatible units, 
several such cases were reported to the NBGRL. In these 
seven cases, six patients (3 anti-Yta, 2 anti-Ge, 1 anti-Lub) were 
transfused with antigen-positive units following a medical 
decision. In these six patients, there were no known adverse 
clinical sequelae.
Table 1. Donors, frozen blood unit inventory, and units requested 












k– 79 204 12 12
Fy(a–b–) 57 148 0 0
Kp(b–) 53 240 5 5
Yt(a–) 51 108 104 84
Lu(b–) 49 145 7 5
GE:–2,3 21 42 5 3
p 12 47 0 0
Group O, D–e– 8 17 0 0
Dr(a–) 7 18 0 0
AnWj– 7 10 1 1
Group O, D–c– 6 11 0 0
P2k 6 10 0 0
Vel– 6* 13 2 1
K:–22 3 6 0 0
JMH– 3 24 0 0
P1k 3 5 0 0
Lan– 3 5 0 0
ABTI– 3 3 0 0
Js(b–) 2 2 0 0
Inab– 2 2 0 0
RAPH:–1 2 8 0 0
Group O, D–c–e– 1 1 0 0
K0 1 10 0 0
Gy(a–) 1 5 0 0
LW(a–) 1 4 0 0
H– 1 3 0 0
H+W 1 11 0 0
GE:–2,–3 1 19 0 0
Total 384 1121 136 111
*One autologous donor.
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In one patient with anti-Yta, an increase in titer was 
observed (64), while being negative using an IgG1/IgG3 gel 
card (Bio-Rad). Because of the increase in titer, provision of 
Yt(a–) units was requested. Moreover, transfusion of Yt(a+) 
blood to patients with anti-Yta is regularly performed by 
some hospitals without reports of adverse effects. In one 
case, an inadvertent transfusion of AnWj+ blood was given 
to a newborn whose mother had anti-AnWj; this transfusion 
caused severe hemolysis.5
Rare Donor Identification
Rare blood donors are identified in a number of ways. 
The first is when a rare antibody specificity is identified in a 
patient specimen. After recovery, the patient can be considered 
for donation either as an autologous or an allogeneic donor. In 
addition, family members, especially siblings, are tested to 
determine whether they share the same antigenic specificity. 
Others are identified when a donor has an antibody to a high-
prevalence antigen or while screening donor samples with 
certain rare antibodies. Occasionally, screening for a specific 
rare phenotype is performed in a targeted population. 
Since 2012, screening for several rare blood types has been 
performed using an automated instrument (PK7200 [PK7300 
since December 2013], Beckman Coulter, Nyon, Switzerland) 
or by manual screening. Of 20,830 donors screened with 
monoclonal anti-Kpb (OSK36, kindly provided by Dr. Y. Tani 
from the Japanese Red Cross), 8 Kp(b–) donors were found. 
Two Vel– donors were identified out of 43,730 donors screened 
utilizing anti-Vel (Donor SP, Blood Bank Umea, diluted 1:40, 
kindly provided by Dr. B. Nilsson-Sojka) and were verified by 
genotyping. Of 3,331 donor samples screened manually with 
our in-house anti-Yta (TE diluted 1:1000), 27 were found to 
be Yt(a–). Among specific donor populations, we manually 
tested 291 samples with anti-Jra (OSK30, kindly provided by 
Dr. Y. Tani from the Japanese Red Cross); 225 samples with 
in-house anti-ABTI, anti-AnWj, and anti-Ge2; and 23 with 
anti-IFC. These screenings identified 38 new rare donors, only 
one of which was AnWj–.
As of 2015, no Rhnull patient or donor has been recorded 
in Israel.
A letter is sent to all rare blood donors with information 
on their rare blood type specificity, the importance of regular 
blood donations, and the opportunity for preservation of rare 
units of blood for themselves as well as for other patients. The 
letter includes an appeal for family members to be tested for 
the specific phenotype, a form to update donor details, and an 
informed consent for units to be sent abroad if needed. 
A wallet-size card with the donor’s name, rare blood type 
and antibody specificity, and recommended phenotype for 
transfusion is also provided.
The recruitment and retaining of rare blood donors requires 
special involvement of devoted personnel.6 At the beginning of 
each year, greeting cards that also encourage blood donation 
are sent. The staff follows inventory levels and if necessary 
donors are called to donate for specific patients. In cases in 
which rare blood is needed urgently, most donors with very 
rare phenotypes willingly donate. A special acknowledgment 
letter is sent to these donors to express our gratitude for their 
immediate response and willingness to assist.
Our center has held two meetings for rare blood donors 
with patient representatives and the NBGRL staff in 2002 and 
2007. The meeting program included lectures on blood types, 
rare blood and blood donations, a musical performance, and, 
most importantly, personal experiences of patients requiring 
rare units of blood and the rare donors who donated the units. 
The donor room was open to allow donors to donate blood, and 
samples were drawn for testing from family members.
One of our major challenges is to reach and retain 
rare blood donors from diverse ethnic populations that are 
underrepresented in our blood donor database. In these 
circumstances, we call the donor, his or her family physician, 
and religious and spiritual leaders or other influential people 
in the community to promote blood donations and testing. As 
MDA-NBS operates blood drives throughout the country, we 
endeavor to arrange blood drives at times and venues that are 
convenient for the donors. Despite all these efforts, at times, 
people with even very rare blood types do not donate regularly 
and some of them have never donated a unit of blood.
From time to time, when there is a complex unresolved 
case or when a rare unit is unavailable, the laboratory requests 
assistance from international resources. Samples are usually 
sent for confirmation or further investigation to the IBGRL in 
Bristol, UK, or to other reference laboratories.
Since 2010, nine rare units of blood were obtained through 
the International Rare Donor Panel operated by the IBGRL 
because compatible blood was not available locally. These rare 
units of blood were kindly provided and shipped to Israel by 
various contributors and included seven Vel– units: six from 
NHS Blood and Transplant, UK, and one from the Transfusion 
Center in Valencia, Spain; and two Jr(a–) units were from the 
Japanese Red Cross Osaka Blood Center. 
The provision of blood internationally—although complex 
logistically and complicated by regulatory issues—is supplied 
within days and arrives in good condition, thanks to the efforts 
and dedication of all parties involved.
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The main challenges facing our NBGRL are to increase 
awareness for blood donation among donors with rare blood 
types and to increase very rare blood availability [such as 
AnWj–, Vel–, Pk, Jr(a–)] by family testing or targeted screening 
using serology or molecular tools. Another important challenge 
is to educate physicians about the clinical significance of the 
antibodies associated with various rare blood types in order to 
improve transfusion of this very limited and unique resource.
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